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Introduction. Since 2001, when Human metapneumovirus (HMPV) was isolated in the Netherlands, the virus has been detected
in several continents. Although reports have confirmed the prevalence of HMPV worldwide, data from Egypt remain limited.
HMPV plays an important role in respiratory tract infections in individuals of all ages particularly in children. This study was
aimed at estimating the prevalence of HMPV in patients with community-acquired lower respiratory infection in Upper Egypt and
characterizing the circulating Egyptian HMPV strains for the first time. Materials and Methods. From 2005 to 2008, respiratory
samples from 520 patients were analyzed for the presence of HMPV by real-time RT-PCR. Molecular and phylogenetic analyses
were performed on partial fusion gene sequences of HMPV-positive patients. Results. HMPV-positive patients were detected in
2007-2008. The overall infection rate was 4%, while 57% of the patients were children. Sequence analysis demonstrated circulation
of subgroup B viruses with predominance of lineage B2. Nucleotide sequence identity within lineage B1 was 98.8%–99.7% and
higher than that in lineage B2 (94.3%–100%). Three new amino acid substitutions (T223N, R229K, and D280N) of lineage B2
were observed. Conclusion. HMPV is a major viral pathogen in the Egyptian population especially in children. During 2007-2008,
predominantly HMPV B2 circulated in Upper Egypt.
1. Introduction
Human metapneumovirus (HMPV) is an enveloped, single-
stranded negative-sense RNA virus that has been classified
in the Metapneumovirus genus of the Paramyxovirus family
[1] and it is most closely related to respiratory syncytial
virus (RSV) [2]. The genetic profile of the virus consists
of 13,350 nucleotides, comprising the nucleoprotein (N),
phosphoprotein (P), matrix protein (M), fusion protein
(F), matrix proteins (M2-1 and M2-2), small hydrophobic
protein (SH), glycoprotein (G), and RNA-dependent RNA
polymerase (L) [3]. The fusion (F) and attachment (G)
proteins are the major HMPV surface glycoproteins. The
HMPV F gene codes for a class 1 viral fusion protein that
mediates virus entry through both attachment [4] and fusion
with the host cell membrane [5]. The HMPV F protein is a
major antigenic determinant whichmediates extensive cross-
lineage neutralization and protection. Infection with each
strain provided a high level of resistance to reinfection with
the homologous or heterologous strain [6]. The F gene is
relatively conserved between subgroups, making it an ideal
target for nucleic acid amplification [7].
Evolutionary analyses suggest that it emerged from
the closely related Avian metapneumovirus C (AMPV-C)
approximately 200 years ago [8, 9]. Productive experimental
infection of poultry with HMPV has not been successful,
and serological studies have failed to detect evidence of
human infection by AMPV [10]. Recent data suggest that
the F protein is responsible for this species restriction. Thus,
Hindawi Publishing Corporation
International Journal of Microbiology
Volume 2014, Article ID 290793, 11 pages
http://dx.doi.org/10.1155/2014/290793
2 International Journal of Microbiology
HMPV infection of humansmay arise from a relatively recent
transspecies transmission from AMPV-C [11].
There is a high seroprevalence of HMPV in sera of
adults older than 40 years old, suggesting that it is a newly
recognized rather than a newly emerging virus [10, 12–17].
Clinical symptoms caused by HMPV infection are sim-
ilar to those of RSV and include fever, cough, wheezing,
dyspnea, rhinorrhea, expectoration, and asthma [18–20].
Several studies have demonstrated that HMPV accounts for a
high proportion of hospitalization for lower respiratory tract
infections (LRTIs) in infants, young children, and other high-
risk populations, such as immunocompromised patients [14,
21–23]. Rates of HMPV infection range from 5.5% to 25%
among children hospitalized with respiratory illness [24–26].
The clinical manifestations of HMPV infection in adults
depend on age and health conditions [2]. In young adults
(aged 14–25 years), the clinical symptoms of HMPV infection
are similar to those of other respiratory viral infections which
include cough, rhinorrhea, and expectoration. In contrast, in
middle aged (aged 26–65 years) and healthy elderly adults
(aged > 65 years), HMPV is similar to influenza infections
and common colds [2]. Although the incidence of HMPV
infection in healthy adults during winter is generally less than
6% [27–29], HMPV is considered to be a major contributor
to the burden of respiratory illnesses in older adults [29].
Phylogenetic analysis of HMPV has identified two sub-
groups, A and B. Both can be subdivided into their genetic
lineages A1 and A2 and B1 and B2, respectively. All virus
variants were identified in various countries in the Americas,
Asia, and Europe [8, 30, 31].
Although reports have confirmed the prevalence of
HMPV worldwide, data from North Africa and the Middle
East remain limited. For the first time, the present study com-
bines epidemiological data on HMPV prevalence andmolec-
ular, phylogenetic analyses of Egyptian HMPV.
2. Materials and Methods
2.1. Study Design. The study was conducted in Assiut Uni-
versity Hospitals. Assiut University Hospitals are one of the
largest hospitals in Egypt and they predominantly give med-
ical services to all the region of Upper Egypt. Upper Egypt is
divided into nine governorates, which are Beni Suef, Menia,
Assiut, Sohag, Qena, Luxor, Aswan, NewValley, and Red Sea.
From December 2005 to February 2008, a prospective
study was conducted with patients admitted to the hospitals
with community-acquired lower respiratory tract infection
(LRTI). The study was approved by the medical ethical com-
mittee at Assiut University Hospitals, and oral consent was
taken from the adult subjects or the children parents prior to
sample collection.
LRTI was diagnosed clinically by the presence of cough
as the main symptom, together with sputum production,
dyspnea, wheeze, or chest discomfort/pain.
All participantswere sampled at the sameday orwithin 24
hours after admission to the hospital. Patients whowere diag-
nosed with LRTI after 48 hours of admission (nosocomial
LRTI) were excluded to ensure the diagnosis of community-
acquired viral infections. During the period of examination,
adults were enrolled during three consecutive winter-spring
seasons, whereas children were enrolled in the season 2007-
2008. According to Assiut University Hospitals’ policy, chil-
dren are those≤14 years old, while adult patients were defined
as patients > 14 years old. All children were presented at the
pediatric outpatient clinic. Adults were either presented at the
chest clinic or admitted to the chest department or the chest
intensive care unit at Assiut University Hospitals (Table 1).
Patients were asked to fill a questionnaire with demographic
and clinical data including age, gender, residence, occupation,
onset of symptoms, date and site of admission, clinical
diagnosis, associated risk factors (smoking, associated car-
diopulmonary condition, immunosuppressive condition, and
other system affections), and antibiotic treatment.
2.2. Sample Collection. In total, 520 patients were prospec-
tively enrolled in this study. To increase the number of
virus-positive samples more than one specimen per patient
was collected. Specimens were nasal swabs (NS), throat
swabs (TS), nasal aspirates (NA), tracheal aspirates (TA),
bronchoalveolar lavages (BL), gargles (G), and sputum (S).
Samples were collected into sterile cups containing phosphate
buffered saline as virus transport medium. Aliquots from
each sample were done and stored at −80∘C until the samples
were finally shipped to the National Influenza Center, Robert
Koch Institute, Germany, where the laboratory and the
phylogenetic analyses were conducted.
2.3. RNA Extraction and Real-Time RT-PCR Assay. Viral
genomic RNA was extracted from 400 𝜇L of the original
samples using RTP DNA/RNA Virus Mini Kit (Invitek,
Germany) according to manufacturers’ instructions. Real-
time PCR assays were carried out to detect HMPV and
other respiratory viruses including influenza A and B viruses
[32, 33], respiratory syncytial virus (RSV A and B) [34], and
adenovirus (AdV) [35]. A two-step RT-PCR method was
used for the detection and amplification of HMPV fusion
gene [36]. The reverse transcription step was performed with
25 𝜇L of the viral RNA and 15 𝜇L of a reaction mixture
containing 200 𝜇M deoxynucleoside triphosphates (dNTPs)
(GE Healthcare, Austria), 5mM dithiothreitol (DTT) (Invit-
rogen, Germany), 0.4mM random primer (Invitrogen, Ger-
many), 20-unit RNasin RNase inhibitor (Promega, USA),
100-unit Moloney murine leukemia virus reverse transcrip-
tase enzyme (M-MLV) (Invitrogen, Germany), and a reaction
buffer (Invitrogen, Germany).The reactionwas carried out in
the thermal cycler T3000 (Biometra, Germany) for 5min at
42∘C, followed by 30min at 37∘C and for 5min at 94∘C. Two
sets of primer-probe pairs were used to detect and amplify
the HMPV fusion (F) gene by real-time PCR (Table 2).
The reaction mixture consisted of PCR buffer (Invitrogen,
Germany), 100 𝜇M dNTPs (GE Healthcare, Austria), 5mM
MgCl
2
(Merck, Germany), 0.5-unit Platinum Taq DNA
polymerase (Invitrogen, Germany), 500 nM of each primer
(Tib Molbiol, Germany), 100 nM of each probe (Applied
Biosystems, USA), and 3.0 𝜇L cDNA with a final volume
of 25 𝜇L. The reaction was performed on the Stratagene
Mx3000 andMx3000P instruments.The PCR thermal profile
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Table 1: Demographic and clinical characteristics of patients.
Patients’ characteristics 𝑁 (%)



























Pediatric outpatient clinic 69 (13)
Chest outpatient clinic 82 (16)
Chest department (inpatient) 264 (51)
Chest intensive care unit (inpatient) 105 (20)
Clinical diagnosis
Bronchopneumonia 106 (20)
Acute bronchitis 73 (14)
Bronchial asthma with infectious exacerbation 72 (14)
Bronchiolitis 29 (6)
Lobar pneumonia 28 (5)
consisted of an initial step of 5min at 95∘C, followed by 45
cycles each consisting of 15 s at 95∘C and 30 s at 60∘C.
2.4. PCR and Sequencing. Partial amplification of the F
protein gene was performed for HMPV-positive samples by
either external or seminested PCR.The reaction mixture was
set up in a total volume of 50 𝜇L containing PCR buffer,
100 𝜇M dNTPs, 3mM MgCl
2
(Merck, Germany), 0.5-unit
Platinum Taq DNA polymerase, 250 nM of each primer, and
5.0 𝜇L DNA template. Amplification was done for 5min at
94∘C followed by 40 cycles at 94∘C for 30 s, 60∘C for 30 s,
and 72∘C for 45 s, with a final extension at 72∘C for 10min.
Primers HMPV-3637-F, HMPV-4192-R1, and R2 were used
for the first-round PCR (Table 2). The amplified products
of 555 bp were visualized by GelRed or Ethidium bromide
staining following electrophoresis on a 2% agarose gel. In case
of negative results, 2𝜇L of the external PCR reaction was
used for semi-nested PCR which was performed in a 50𝜇L
reaction with 250 nM each of the primers HMPV-3637-F
andHMPV-4164-R (Table 2).The nested amplicons of 527 bp
were visualized by agarose gel electrophoresis as well.
Before sequencing, amplicons were purified either
directly using the MSB Spin PCRapace kit (Invitek,
Germany) or extracted from agarose gel using JETquick
Gel Extraction Spin kit (Genomed, Germany) according
to the manufacturer’s instructions. Purified PCR products
were cycle sequenced with primer pairs previously used for
external and semi-nested PCR, respectively, in an ABI-Prism
3130xl Genetic Analyzer (Applied Biosystems, Germany)
using the Big Dye Terminator v3.1 Cycle Sequencing kit
(Applied Biosystems, Germany).
2.5. Phylogenetic and Molecular Analysis. A multiple
sequence alignment was compiled from a part (439 nt) of
the FI subunit of the F gene using ClustalW in the MEGA
version 4.0 software program [37]. In MEGA, the Neighbor-
Joining tree was calculated with the HKY85 model and a
reliability of 1,000 replicates.Thephylogenetic treewas rooted
to Avian metapneumovirus C (AMPV-C). The following
sequences of the described HMPV subgroups and lineages
were included in the phylogenetic analysis: DQ009484
(AMPV-C), AY145288 (CAN98-73), AY145289 (CAN98-75),
AY145290 (CAN98-76), AY145296 (CAN97-83), AY145297
(CAN00-12), AY145298 (CAN00-13), AY145299 (CAN00-
14), AF371337 (NL/1/00), AY304360 (NL/17/00), Y304361
(NL/1/99), AY304362 (NL/1/94), DQ362939 (Arg/1/98),
DQ362944 (Arg/1/99), DQ362947 (Arg/1/00), EU857567
(TN/94/1-1), EU857569 (TN/89/7-13), EU857570 (TN/97/2-
37), EU857571 (TN/98/2-42), EU857572 (TN/87/2-7),
EU857573 (TN/88/4-21), EU857581 (TN/99/4-19), EU857587
(TN/94/4-13), EU857592 (TN/92/10-32), EU857594 (TN/01/
2-8), EU857595 (TN/98/5-12), EU857599 (TN/91/5-21),
HQ456590 (GER/2499/04), HQ456598 (GER/0394/06),
HQ456606 (GER/0513/07), HQ456611 (GER/0043/08),
HQ456613 (GER/0259/08), HQ456617 (GER/0562/08),
HQ456633 (GER/3379/10). The GenBank accession numbers
of the Egyptian HMPV sequences are JQ041674, JQ041675,
HQ909765, JQ041676, HQ909766, and JQ041677-JQ041695.
Pairwise nucleotide and amino acid identity within and
between the genetic lineages B1 and B2 was calculated using
the Bioedit version 7.2.3 [38].
2.6. Statistical Analysis. The SPSS program version 16.0 was
used for the calculation of unpaired 𝑡-test and the Fisher’s
exact test, respectively.
3. Results
3.1. Study Population. From 2005 to 2008, a total of 520
patients with community-acquired LRTI were prospectively
enrolled in this study. Almost all patients (99%) were
residents of Upper Egypt and of different age groups (Table 1).
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Table 2: HMPV oligonucleotide primers and probes.
Name Oligonucleotide sequence (5󸀠-3󸀠) Positiona Gene Polarity Reference
Real-time PCR
HMPV F S gCTCCgTAATYTACATggTgCA 794–815 F + [36]
HMPV F S1 gAAgCTCYgTgATTTACATggTYCA 791–815 F + [36]
HMPV F AS gACCCTgCARTCTgACAATACCA 924–947 F − [36]
HMPV F AS1 AgTKgATCCTgCATTTTTACAATACCA 924–951 F − [36]
HMPV F TMGB F-CCYTgCTggATAgTAAAA-MGB 844–861 F + [36]
HMPV F TMGB1 F-CCTTgTTggATAATCAA-MGB 844–860 F + [36]
Conventional PCR and sequencing
External PCR
HMPV-3637-F gTYAgCTTCAgTCAATTCAACAgAAg 571–596 F + [31]
HMPV-4192-R1 CAgTgCAACCATACTgATRggATg 1101–1125 F − [36]
HMPV-4192-R2 TAgTgCAACCATACTgATRgggTg 1101–1125 F − [36]
Seminested PCR
HMPV-3637-F gTYAgCTTCAgTCAATTCAACAgAAg 571–596 F + [31]
HMPV-4164-R CCTgTgCTRACTTTgCATggg 1077–1097 F − [36]
aNucleotide positions are given according to the gene positions in HMPV isolate NL/1/94 (GenBank accession number AY304362). The base “G” is given in
lower letters to avoid confusion with “C.” Abbreviations: F: 6󸀠-carboxyfluorescein (FAM); MGB: minor groove binder; nucleic acid codes: Y: C/T, R: A/G, and
K: T/G.
Table 3: Detection of respiratory viruses in patients with LRTI (children/adults).
Season Number of investigated patients Virus-positive patients
HMPV RSV Influenza virus Adenovirus Number of coinfections
2005-2006 22 (0/22) 0 0 1 0 0
2006-2007 278 (0/278) 0 2 15 12 0
2007-2008 220 (70/150) 21 (12/9) 14 (12/2) 6 (1/5) 8 (7/1) 4 (3/1)
Total 520 (69/451) 21 (12/9) 16 (12/4) 22 (1/21) 20 (7/13) 4 (3/1)
Percent 100 (13/87) 4.0 (17/2) 3 (17/1) 4.2 (1/5) 3.8 (10/3) 0.8 (4/0)
Next to Egyptian patients, one patient was originally from
Yemeni Republic who came to Egypt to seek medical care
(Table 1). Children represented 13% (69 patients) of the study
population, while adults represented 87% (451 patients).
The mean age of children was 2.7 years and the median
age was 1 year. For the adults, the mean age was 47.9 years
and the median age was 49 years. Male children and adults
constituted 55% and 61%, respectively. During the period of
examination, samples from adults were collected within three
consecutive winter-spring seasons, whereas children were
prospectively enrolled in the season 2007-2008 (Table 3).
Of the 520 patients, 369 (71%) were hospitalized, 106
(20%) suffered frombronchopneumonia, 73 (14%) fromacute
bronchitis, and other furthers from different diseases of the
lung (Table 1).
3.2. Detection of HMPV and Other Respiratory Viruses by
Real-Time PCR. A viral agent was detected in 79 (15.2%)
patients of the study population (Table 3). Thirty two of
the positive patients were children (accounting for 46% of
the total number of children enrolled in the study) and 47
were adults (accounting for 10% of the adult group). Of the
positive patients, 22 (4.2%) were infected by influenza virus,
20 (3.8%) by adenovirus (AdV), and 16 (3%) by RSV. HMPV
was detected in 21 patients (4.0%). In total, four coinfections
were identified: three co-infections with RSVA and AdV and
one coinfection with HMPV and AdV (Table 3).
All HMPV-positive cases were detected during the season
2007-2008, while RSV and AdV were detected from 2006
to 2008. Influenza virus was present in all of the three
seasons investigated (Table 3). The seasonal distribution of
the respiratory viruses during the period of examination
is shown in Figure 1. HMPV was detected in January and
February of the season 2007-2008.
3.3. Characteristics of HMPV-Positive Patients. Among the
twenty-one HMPV-positive patients, 12 (57%) were children.
While all of the children were outpatients, 2 of 9 adults
were inpatients admitted to the chest department. Thus, the
majority (90%) of HMPV-infected patients were treated in
ambulantmedical surgeries (Table 4). Patients were primarily
residents of Assiut (80%), followed by residents of the
governarates Red Sea, Qena, Aswan, and Luxor (each 5%).
The most clinical signs significantly associated with the
presence of HMPV were acute bronchitis (unpaired 𝑡-test,
𝑃 = 0.022), bronchial asthma with infection exacerbation
(𝑃 = 0.019), and bronchiolitis (𝑃 = 0.0001) (Table 4).
Acute bronchitis was the most common diagnosis in adults
(44%), whereas bronchiolitis was most frequently diagnosed
in children (50%). Further, there was one two-year old patient
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Table 4: Clinical characteristics of HMPV infections.
Patient Age Gender Residence Smokingpattern Specimens In-/outpatient
Underlying
disease Clinical diagnosis
EG/303 56 y F Red Sea None NA, G, and S Outpatient None Acute bronchitis
EG/318 27 y F Qena None NS, G, and S Outpatient None Acute bronchitis
EG/327 55 y M Assiut None NS, G, and S Outpatient None Bronchial asthma with infectiousexacerbation
EG/332 6mo M Assiut None NS, TS Outpatient None Bronchiolitis
EG/339 2 y M Assiut None NS, TS Outpatient None Bronchiolitis
EG/341 2 y F Assiut None NS, TS Outpatient None Bronchiolitis
EG/347 2mo F Assiut None NS, TS Outpatient None Bronchiolitis
EG/349 2 y F Assiut None NS, TS Outpatient None Bronchial asthma with infectiousexacerbation
EG/352 2 y M Assiut None NS, TS Outpatient None Bronchiolitis
EG/353 6mo F Assiut None NS, TS Outpatient None Bronchiolitis
EG/377 3 y F Assiut None NS, TS Outpatient None
Bronchial asthma with infectious
exacerbation, tonsillitis, and
pharyngitis
EG/393 2 y M Assiut None NS, TS Outpatient None
Bronchial asthma with infectious
exacerbation, tonsillitis, and
pharyngitis
EG/433 24 y M Assiut Mild NS, TS, and G Inpatient None
Multiple pyemic abscesses (septic
embolism), acute infective septic
endocarditis
EG/444 22 y F Assiut None NS, G Outpatient None Lobar pneumonia
EG/449 1 y M Assiut None NS, TS Outpatient None Bronchopneumonia
EG/457 8mo M Aswan None NS, TS Outpatient None Bronchopneumonia
EG/459 5 y F Assiut None NS, TS Outpatient None Acute bronchitis, tonsillitis, andpharyngitis
EG/472 60 y F Assiut None NS, G, and S Outpatient None Acute bronchitis
EG/476 47 y M Assiut None NS, G Outpatient Bilateralhydronephrosis Acute bronchitis
EG/478 56 y F Assiut None NS, G Outpatient Hypertension Bronchial asthma with infectiousexacerbation
EG/513 66 y M Luxor None NS, TS, and BL Inpatient None Bronchopneumonia
Abbreviations: NS: nasal swab; G: gargle; TS: throat swab; BL: bronchoalveolar lavage; S: sputum.
(EG/347) coinfected with AdV. Patients EG/476 and EG/478
suffered from the underlying diseases bilateral hydrone-
phrosis and hypertension, respectively.
To describe the circulation of HMPV in the Egyptian
population, patients were grouped by age: 0–4 years, 5–14
years, 15–34 years, 35–60 years, and >60 years (Figure 2).
HMPV infections occurred in patients from all age groups
but were most common among children between 0 and 4
years (Fisher’s exact test, 𝑃 = 0.0001).
3.4. Phylogenetic Analysis of HMPV. Partial amplification
of the F protein gene was performed for 32 specimens of
the 21 HMPV-positive patients. Except for patient EG/459,
partial fusion gene sequences were obtained for all other
patients. Sequences were obtained from 24 specimens out of
the 32 HMPV-positive specimens (75%). Phylogenetic ana-
lysis was conducted on Egyptian HMPV sequences of 439 nt
of the F gene. At present, HMPV is differentiated into
subgroups A and B, each with two genetic lineages A1, A2,
B1, and B2, respectively. All the Egyptian HMPV sequences
clustered in subgroup B (Figure 3). Of the 24 Egyptian
sequences 3 belonged to lineage B1 and 21 to lineage B2.
Thus, 3 patients (15%) were infected with HMPV of lin-
eage B1 and 17 patients (85%) were infected with HMPV of
the lineage B2. There were Egyptian HMPV sequences iden-
tical (GER/3379/10, GER/0562/08) or closely related (GER/
0394/06, GER/0259/08, and GER/0043/08) to sequences
from Germany. Further, the Egyptian sequences clustered
in batches of nearly identical (lineage B1) or identical (in line-
age B2) sequences. HMPV sequences EG/303(NA)/08 and
EG/513(TS)/08 of lineage B2 clustered separately from the
other Egyptian sequences of the same lineage.These sequenc-
es were detected in patients resident in Red Sea and Luxor.
3.5. Molecular Analysis of HMPV. The nucleotide identity
between lineages B1 and B2 was 94.3%–95.2%, whereas it
was 98.8%–99.7% and 94.3%–100% within lineages B1 and
B2, respectively (Table 5).The sequences between lineages B1
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Table 5: Genetic similarity between and within HMPV subgroups and lineages (F, fusion gene).
Study Country Nucleotide sequence identity (%) Amino acid sequence identity (%)
B1 B2 B1-B2 A-B B1 B2 B1-B2 A-B
This study Egypt 98.8–99.7 94.3–100 94.3–95.2 — 99.3–100 97.2–100 97.2–98.6 —
[8] The Netherlands 97–100 97–100 94–96 84–86 99-100 99-100 97–99 94–97
[18] Canada — — 94.3–99.9 83.0–83.6 — — 98.3–99.8 94.1–95.4
[31] Germany 97.1–99.8 98.3–99.5 94.0–95.7 83.6–87.4 — — — —
[59] Many countries 96.0–99.9 97.2–99.4 92.0–94.1 81.5–85.3 99.5–100 99.1–100 98.1–99.1 93.1–96.3
[39] USA 98–100 96–100 93–95 — 100 99.4 98.4 —
[60] France 97.2–100 97.2–100 92.6–94.4 82.7–86.5 — — — —
[61] Cambodia — 97.3–100 92.6–100 — — 97.8–100 97.2–100 —
Table 6: Lineage-specific amino acid substitutions in the HMPV F gene between positions 209 and 353.
Lineage Amino acid position in the F gene of Egyptian sequences
223 229 231 233 280 286 296 312 348
B1 (𝑛 = 3) R→K (𝑛 = 2) V→E (𝑛 = 1) Y I N K R























































































Figure 1: Monthly distribution of respiratory viruses causing LRTI.
From 2005 to 2008, respiratory samples from patients with LRTI
were collected and investigated for the presence of RSV, AdV,
HMPV, and FLU. The gray shaded area in this figure shows the
number of investigated samples per month. Each number of virus-
positive samples is represented both with a bar and absolute values
in the abscissa.
and B2 shared an amino acid identity of 97.2%–98.6% and
within lineages B1 and B2 of 99.3%–100% and 97.2%–100%,
respectively. Lineage B2 was the most divergent. The analysis
of sequence similarity showed greater nucleotide than amino
acid diversity as determined by other studies [8, 18, 39] from
for example, The Netherlands, Canada, or USA, respectively
(Table 5).
There were five amino acid residues (233, 286, 296,
312, and 348) common to subgroup B strains (Table 6).
Single amino acid variations were present in one, two,
or few sequences. The highest amino acid variability was
observed for twelve sequences of the lineage B2 (Figure 4).
They all exhibit additional unique amino acid substitutions
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Figure 2: Number of HMPV infections in different age groups
( ∗𝑃 = 0.0001).
(Figure 3) revealed that these twelve sequences clustered sep-
arately and were closely related to sequences from Germany
(GER/3379/10 and GER/0513/07). Interestingly, there were
two Egyptian strains (EG/303(NA)/08 and EG/513(TS)/08)
which comprise an additional but different amino acid sub-
stitution at residue 229 (Table 6). These sequences clustered
separately from the other Egyptian strains (see above).
4. Discussion
This study was performed to estimate the prevalence of
HMPV in patients with community-acquired lower respira-
tory tract infection in Upper Egypt, and more important, to
give new insights into circulating HMPV strains in Egypt at
all.
The overall proportion of HMPV infections in Upper
Egypt between 2005 and 2008 was 4% with a frequency
rate of 17% in the children’s group. In the area of greater
Cairo (Egypt) the positive rate in children was 6.4% in 2006-
2007 [40]. Another study of HMPV infection in children of
















































































Figure 3: Phylogenetic tree of partial F gene sequences of Egyptian HMPV.The tree was generated with Neighbor-Joining method with 1,000
bootstrap replicates and rooted to Avian metapneumovirus C (AMPV-C). Reference sequences representing the different HMPV genetic
lineages were additionally included in the analysis. Egyptian viruses are shown in boldface. These viruses are identified by the geographic
location, patient number, type of specimen, and year of isolation. The scale bar represents 2% of nucleotide changes between close relatives.
Mansoura, northeast part of Egypt, in 2010 showed a positive
rate of 8% [41]. Further, in comparison to our study, the
infection rate of HMPV in children is at an equal frequency
level in the Arabian Peninsula. From July 2007 to November
2008 an incidence of 8.3% was observed in Saudi Arabia
[42], whereas the frequency rate of HMPV was 12.7% in
hospitalized children from Jordan in 2007 [43].
While the HMPV frequency in children was 17%, the
infection rate in the adult population was 2% in our study. In
a different study fromEgypt from 2007 to 2009, a positive rate
of 13.6%was observed [19], which is higher than the infection
rate of adults in this study.The higher infection rate ofHMPV
in children supports the hypothesis that HMPV is a leading
cause of respiratory tract infection in the first years of life [44].
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Figure 4: Amino acid alignment of partial F protein gene of HMPV. Predicted amino acid sequences of Egyptian HMPV B were compared
with the corresponding sequence of the prototype strain NL/1/00 (GenBank accession number AF371337). Identical residues are indicated by
dots. The Egyptian HMPV is identified by the geographic location (EG), patient number, type of specimen, and year of isolation.
In general, the HMPV frequency rate varies worldwide from
3.5% in Finland to 17.8% in Brazil [45–50]. Altogether, the
frequency of HMPV varies from year to year in a given region
depending on the geographical locations, and furthermore
the positive rate alters due to different methods of sample
collection and variation of calculation methods [43, 51].
The clinical manifestations of HMPV-infected patients
are mainly mild upper-airway diseases [52]. In our study, this
is reflected by the presentation of HMPV-infected patients at
the outpatient clinic (90%).Nevertheless,HMPVcan be asso-
ciated with severe disease of the lower respiratory tract. One
major clinical diagnosis in the present study was pneumonia
which was found in 20% of the infected HMPV patients.
Similar findings were observed in Egyptian adults in the same
time period (2007–2009) with a frequency of 17% for pneu-
monia [19].The common clinical diagnosis noted in children
withHMPV in the present study was bronchiolitis, which can
be supported by data fromEgypt, USA, and Brazil [23, 41, 53].
Next to single HMPV infection, co-infections of HMPV
with different respiratory pathogens occur. The co-infection
rate (0.8%) in this study was low. We detected three co-
infections in children (4.3%) and one co-infection in adults
(0.2%). With regard to HMPV, there was one co-infection
with HMPV and AdV identified in an infant. In a different
study from Egypt conducted in 2006-2007, a comparable co-
infection rate in children (4.5%) to our results was observed
[40]. Interestingly, a study in China revealed a co-infection
frequency of 58% in HMPV-positive children [54]. Co-
infections with HMPV are often described for children [55,
56] and were mostly associated with the age group less than
6 months old [57].
To investigate the genetic variability of the HMPV strains
in Upper Egypt, a stretch of 439 nt of the fusion gene was
analyzed.The phylogenetic analysis was both performedwith
German strains and other published reference strains repre-
senting HMPV subgroups A and B. The Egyptian sequences
clustered in HMPV subgroup B with predominance of the
genetic lineage B2. Whereas in Upper Egypt HMPV B circu-
lated in the season 2007-2008, in Jordan (Arabian Peninsula)
both subgroups were detected in 2007 [43]. HMPV subgroup
A was detected in 93% of the patients and 28.6% of the
patients were infected with subgroup B. Co-infection with
HMPV subgroups A and B was detected in 21,4% [43]. These
different circulation patterns in the same area support the
assumption that the circulation ofHMPVsubgroups and sub-
clusters might be a local phenomenon [58].
In this study, a high degree of identity was observed in
the F gene amongmost of the Egyptian sequences at both the
nucleotide and amino acid levels. In line with these findings,
the F gene was well conserved in HMPV circulating in
Europe, North America, and Asia [8, 18, 31, 59–61] (Table 5).
The amino acid conservation of the F gene was higher in the
Egyptian strains than nucleotide sequence conservation.This
is supported by the assumption that nucleotide diversity is
greater than amino acid diversity among HMPV F sequences
due to functional constraints on fusion proteins which
prevent drastic amino acid changes. This could lead to a lack
of directional antigenic drift in paramyxoviruses in contrast
to influenza viruses [62].
Our phylogenetic analysis demonstrated the cocircula-
tion of the genetic lineages B1 and B2 during season 2007-
2008. HMPV lineage B2 was predominant in that season.The
Egyptian HMPV strains formed three clusters, two in the B2
branch and one in the B1 branch. In regard of the amino acid
substitution, it was revealed that B2 strains were more vari-
able than B1 strains. Two Egyptian HMPV (EG/303(NA)/08
and EG/513(TS)/08) showed a unique amino acid substitu-
tion in the F gene resulting in an allocation of these strains to a
separate branch from B2 viruses.These viruses were detected
in two patients from Red Sea and Luxor. Interestingly, there
were Egyptian and German HMPV strains which were very
closely related. The relation of HMPV from distant regions
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is known but reasons remain unclear. It can be supposed
that human travelling behaviour influences the diversity and
evolution of HMPV.
5. Conclusion
Human metapneumovirus is an important respiratory viral
pathogen in the Egyptian patient population especially chil-
dren. The phylogenetic analysis of Egyptian HMPV isolates
showed the circulation of viral group B during season 2007-
2008 with predominance of lineage B2. Our study provides
new insights into the epidemiology of HMPV in Egypt.
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neumovirus in viral respiratory infections in young children,”
Journal of Clinical Microbiology, vol. 44, no. 8, pp. 2739–2742,
2006.
[46] L.M.Thomazelli, S. Vieira, A. L. Leal et al., “Surveillance of eight
respiratory viruses in clinical samples of pediatric patients in
Southeast Brazil,” Jornal de Pediatria, vol. 83, no. 5, pp. 422–428,
2007.
[47] A. Sarasini, E. Percivalle, F. Rovida et al., “Detection and patho-
genicity of human metapneumovirus respiratory infection in
pediatric Italian patients during awinter-spring season,” Journal
of Clinical Virology, vol. 35, no. 1, pp. 59–68, 2006.
[48] W. Ji, Y. Wang, Z. Chen, X. Shao, Z. Ji, and J. Xu, “Humanmeta-
pneumovirus in children with acute respiratory tract infections
in Suzhou,China 2005-2006,” Scandinavian Journal of Infectious
Diseases, vol. 41, no. 10, pp. 735–744, 2009.
[49] F. Esper, D. Boucher, C.Weibel, R. A.Martinello, and J. S. Kahn,
“Human metapneumovirus infection in the United States: clin-
ical manifestations associated with a newly emerging respira-
tory infection in children,” Pediatrics, vol. 111, no. 6 I, pp. 1407–
1410, 2003.
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